Trump health nominee backs some U.S. bargaining on drug prices
Published
4 Min Read
More From Employee Benefit News
What Trump’s ‘Great Healthcare Plan’ means for drug costs and price transparency
The legislation calls on Congress to lower prescription drug costs, shift subsidies directly to consumers, and enforce strict price transparency.
Healthcare costs are forcing employers to reconsider their benefits strategy
Employers are under pressure to keep benefits competitive while controlling costs, driving new scrutiny of PBMs, hospital prices and GLP-1 coverage for 2027.
GLP-1s push health plan costs to 15-year high
Rising use of the weight-loss drug is fueling the fastest health plan cost growth in a decade and a half, forcing employers to rethink coverage strategies and cost management.
Women on GLP-1s and hormone therapy seek better clinical support
Metabolism-management drugs and hormone therapy are growing in popularity, but women need expert clinical oversight in conjunction with medication access.
With or without GLP-1s, your business needs a metabolic health strategy
To truly flip the script on metabolic disease, benefit leaders must build a cost-efficient, supportive plan for employees and their business.
